Drugmaker Actavis said on Tuesday that it will buy Forest Laboratories for approximately $25 billion. The deal stands to give Actavis a broader portfolio of pharmaceuticals, which would enable the combined company to sell more products to doctors and hospitals, according to James Molloy, Managing Director at Janney Montgomery Scott. Molloy explains why he believes the deal is a smart one for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
